{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.3","value":"124.36"},{"groupId":"OG001","spread":"23.33","value":"108.25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"302"},{"groupId":"OG001","value":"83"}],"units":"Participants"}],"description":"The QOL assessments questionnaire should be completed via the tablet provided by the study or on any available computer with an internet connection. The FACT-B questionnaire consists of five subscale, listed below:\n\nPhysical well being(PWB): range 0-28 Social/Family well being(SWB): range 0-28 Emotional well being(EWB): range 0-24 Functional well being(FWB): range 0-28 Breast cancer subscale(BCS): range 0-40 The total score (FACTB) is calculated by summarizing all the subscales listed above, therefore it ranges from 0 to 148. The higher the score the better the outcome (applies to all sub-scales as well).","dispersionType":"Standard Deviation","groups":[{"description":"T-DM1 3.6mg/kg every three weeks by IV for 17 doses for a total of 51 weeks","id":"OG000","title":"Trastuzumab Emtansine (T-DM1)"},{"description":"paclitaxel 80 mg/m2 IV weekly and trastuzumab 4 mg/kg IV load, followed by 2 mg/kg IV weekly for 12 weeks, followed by trastuzumab 6 mg/kg IV every 3 weeks for 13 treatments","id":"OG001","title":"Paclitaxel + Trastuzumab"}],"paramType":"MEAN","populationDescription":"not all patients required to complete the QOL","reportingStatus":"POSTED","timeFrame":"at week 12","title":"Quality of Life (QOL) FACT B Total Score at Week 12","type":"SECONDARY","unitOfMeasure":"score on a scale"}